BRCA1 and prostate carcinoma: Targeting the DDR to treat cancer has gained considerable traction following the successful deployment of PARP inhibitors (PARPi) in the treatment of breast, ovarian, and prostate cancers that harbor mutations in BRCA1 and 2.